New research has raised concerns that popular weight-loss injections like Ozempic and Mounjaro, while potentially offering protection against some tumours and providing other health benefits, may increase the risk of kidney cancer. This alarm comes from the largest study to date, published in JAMA Oncology, which tracked nearly 44,000 overweight and obese individuals for up to ten years.

While the study found a significant 17 percent lower overall risk of cancer among patients on these slimming jabs, including substantial reductions in ovarian and womb tumours, a disturbing signal for kidney cancer emerged. Patients using these injections were approximately one-third more likely to develop kidney cancer compared to those who did not. This increased risk was particularly pronounced among individuals under 65 years old and those who were overweight.

Kidney cancer is often dubbed a 'silent killer' because it typically shows no symptoms until it has reached an advanced stage, making early detection difficult. Symptoms such as blood in the urine, persistent back pain, or a lump under the ribs usually appear when treatment becomes less effective. It is one of the fastest-rising cancers in both Britain and the US, with cases also climbing sharply among younger adults, a trend partly attributed to rising rates of obesity and high blood pressure.

The study compared 43,317 people prescribed the jabs with 43,315 who did not take them, finding 83 kidney cancer cases among users versus 58 among non-users. Dr. Hao Dai, who led the research, expressed concern and called for further observational studies to confirm this potential link. Several theories are being explored to explain this possible increase in kidney cancer risk, including the drugs' common side effects like severe nausea, vomiting, and dehydration, which could lead to acute kidney injury. Another theory considers the presence of GLP-1 receptors in the kidneys, which are targeted by these drugs, raising questions about whether constant stimulation could cause uncontrolled cell growth. Rapid weight loss and metabolic shifts induced by the drugs are also being investigated as potential factors.

Despite these findings, experts urge caution in interpreting the data. Professor Paul Pharoah emphasized that an association does not necessarily imply causation. Dr. Stephen Lawrence noted the slight uptick in cases, about six extra cases per 10,000 patients treated over a year, considering it a small increase when weighed against the drugs' broader health benefits. These benefits include a reduced risk of heart attacks, strokes, and kidney disease, in addition to their primary weight-loss effects. Experts stress that while these drugs may offer protection against some cancers, continued vigilance for warning signs of kidney disease is essential.